Posted on 7월 11, 20247/11/24
Key Insights from ARCS 2024: Shaping the Future of HTA and Reimbursement in Australia
Posted on 8월 1, 20238/1/23
Commercial Key Success Factors (KSFs) for Global Drug Development Programs
Posted on 4월 17, 20234/17/23
What EVERSANA’s Growing Abstract Count at ISPOR U.S. Means to the HEOR Industry
Posted on 10월 12, 202210/12/22
The Evolution of HTA and Its Impact on Drug Prices in Japan
Posted on 4월 14, 20224/14/22
Impact of Patient Reported Outcome Measures on HTA Decisions for Rare Diseases
Posted on 4월 1, 20224/1/22
What You Need to Know as the European Union Embarks on Joint Health Technology Assessment (HTA)
Posted on 12월 21, 202112/21/21